Eupraxia Pharmaceuticals (TSX:EPRX) Tariff Resilience Score: 5/10 (As of Jul. 09, 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
34 GF Score
Price C$9.80
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals Tariff Resilience Score?

Eupraxia Pharmaceuticals TSX:EPRX +3.38% 34 Tariff Resilience Score is 5 as of Jul. 09, 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,368 Biotechnology companies, Eupraxia Pharmaceuticals ranks better than 62.43% on this metric.

Eupraxia Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Eupraxia Pharmaceuticals has Pharmaceutical company with potential exposure to tariffs on imported raw materials. Industry-specific exemptions and strategic sourcing reduce some risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Eupraxia Pharmaceuticals might have Average Resilient.

Eupraxia Pharmaceuticals  (TSX:EPRX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Eupraxia Pharmaceuticals Tariff Resilience Score Related Terms

TSX:EPRX vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's Tariff Resilience Score falls into.


TSX:EPRX
34GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a Tariff Resilience Score of 5 as of Jul. 09, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #514 out of 1368 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Eupraxia Pharmaceuticals' Tariff Resilience Score too high?
Eupraxia Pharmaceuticals' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Eupraxia Pharmaceuticals' value of 5 is 25% above this industry median. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #514 out of 1368 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #514 out of 1368 companies for Tariff Resilience Score. This puts Eupraxia Pharmaceuticals in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Eupraxia Pharmaceuticals' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,368 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eupraxia Pharmaceuticals's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eupraxia Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Eupraxia Pharmaceuticals' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current Tariff Resilience Score is 5 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
34GF Score

Get the complete analysis for TSX:EPRX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.80
Price